The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-β-mediated growth inhibition of myeloid cells

Blood

Volumn 92, Issue 11, 1998, Pages 4003-4012

  Kurokawa, Mineo ^b   Mitani, Kinuko ^b   Imai, Yoichi ^b   Ogawa, Seishi ^b   Yazaki, Yoshio ^b   Hirai, Hisamaru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; ZINC FINGER PROTEIN;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CHROMOSOME 21Q; CHROMOSOME 3Q; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 3; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0032400836     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.11.4003.423a56_4003_4012     Document Type: Article

References (87)

1. Rubin CM, Larson RAJ, Anatasi-Winter JN, Thangavelu M, Vardiman JW, Rowley JD, Le Beau MM: t(3;21)(q26;q22): A recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 76:2594, 1990
2. Schneider NR, Bowman WP, Frenkel EP: Translocation (3;21)(q26; q22) in secondary leukemia. Ann Genet 34:256, 1991
3. Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M, Hirai H: Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 13:504, 1994
4. Look AT: Oncogenic transcription factors in the human acute leukemias. Science 278:1059, 1997
5. Kagoshima H, Shigesada K, Satake M, Ito Y, Miyoshi M. Ohki M, Pepling M, Gergen P: The Runt-domain identifies a new family of heterodimeric transcriptional factor. Trends Genet 9:338, 1993
6. Ogawa E, Inuzuka M, Maruyama M, Satake M, Naito FM, Ito Y, Shigesada K: Molecular cloning and characterization of PEBP2β, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2α. Virology 194:314, 1993
7. Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA: Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 13:3324, 1993
8. Hsiang YH, Spencer D, Wang S, Speck NA, Raulet DH: The role of viral enhancer "core" motif-related sequences in regulating T cell receptor-gamma and -delta gene expression. J Immunol 150:3905, 1993
9. Meyers S, Downing JR, Hiebert SW: Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13:6336, 1993
10. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD: PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2β/CBFβ proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol 14:5558, 1994
11. Suzow J, Friedman AD: The murine myeloperoxidase promoter contains several functional elements, one of which binds a cell type restricted transcription factor, myeloid nuclear factor l (MyNF1). Mol Cell Biol 13:2141, 1993
12. Uchida H, Zhang J, Nimer SD: AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol 158:2251, 1997
13. Zhang DE, Hetherington CJ, Shapiro LH, Chen HM, Look AT, Tenen DC: CCAAT enhancer-binding protein (C/EBP) and AML1 (CBFα2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol 16:1231, 1994
14. Tanaka T, Tanaka K, Ogawa S, Kurokawa M, Mitani K, Nishida J, Shibata Y, Yazaki Y, Hirai H: An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J 14:341, 1995
15. Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse H3, Jenkins NA, Copeland NG: Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 8:301, 1988
16. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN: Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54:831, 1988
17. Morishita K, Parganas E, Douglass EC, Ihle JN: Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene 5:963, 1990
18. Morishita K, Parganas E, William CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB, Ihle JN: Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 89:3937, 1992
19. Levy ER, Parganas E, Morishita K, Fichelson S, James L, Oscier D, Gisselbrecht S, Ihle JN, Buckle VJ: DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. Blood 83:1348, 1994
20. Ogawa S, Kurokawa M, Tanaka T, Mitani K, Inazawa J, Hangaishi A, Tanaka K, Matsuo Y, Minowada J, Tsubota T, Yazaki Y, Hirai H: Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. Oncogene 13:183, 1996
21. Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den Berghe H. Marynen P: Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 57:564, 1997
22. Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, Ihle J, Taetle R: Expression of EVI1 in myelodysplastic syndromes and other hématologic malignancies without 3q26 translocations. Blood 84:1243, 1994
23. Ogawa S, Kurokawa M, Tanaka T, Tanaka K, Hangaishi A, Mitani K, Kamada N, Yazaki Y, Hirai H: Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia 10:788, 1996
24. Lopingco MC, Perkins AS: Molecular analysis of Evil, a zinc finger oncogene involved in myeloid leukemia. Curr Top Microbiol Immunol 211:211, 1996
25. Bartholomew C, Kilbey A, Clark AM, Walker M: The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene 14:569,1997
26. Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y, Hirai H: Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 269:24020, 1994
27. Kurokawa M, Ogawa S, Tanaka T, Mitani K, Yazaki Y, Witte ON, Hirai H: The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogene 11:833, 1995
28. Morishita K, Parganas E, Matsugi T, Ihle JN: Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol 12:183, 1992
29. Kreider BL, Orkin SH, Ihle JN: Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Proc Natl Acad Sci USA 90:6454, 1993
30. Massagué J: The transforming growth factor-β family. Annu Rev Cell Biol 6:597, 1990
31. Roberts AB, Sporn MB: The transforming factor-βs. Heidelberg, Germany, Springer Verlag, 1990
32. Kingsley DM: The TGF-β superfamily: New members, new receptors, and new genetic tests of function in different organisms. Gen Dev 8:133, 1994
33. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM: Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 139:1347, 1995
34. Derynck R, Zhang Y: Intracellular signalling: the mad way to do it. Curr Biol 6:1226, 1996
35. Massagué J: TGFβ signaling: receptors, transducers, and Mad proteins. Cell 85:947, 1996
36. Wrana JL, Attisano L: MAD-related proteins in TGFβ signaling. Trends Genet 12:493, 1996
37. Baker JC, Harland RM: A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway. Gen Dev 10:1880, 1996
38. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L: MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543, 1996
39. Lagna G, Hata A, Hemmati BA, Massagué J: Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature 383:832, 1996
40. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL: MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 87:1215, 1996
41. Zhang Y, Feng X, We R, Derynck R: Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 383:168, 1996
42. Nakao A, Imamura T, Souchelnitskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai K, Heldin C-H, Miyazono K. ten-Dike P: TGF-β receptor-mediated signalling through Smad2. Smad3 and Smad4. EMBO J 16:5353, 1997
43. Kim J, Johnson K, Chen HJ, Carroll S, Laughon A: Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic. Nature 388:304, 1997
44. Chen X, Rubock MJ, Whitman M: A transcriptional partner for MAD proteins in TGF-β signalling. Nature 383:691, 1996
45. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M: Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 389:85, 1997
46. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Yazaki Y, Matsumoto K, Hirai H: The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3. Nature 394:92, 1998
47. Tanaka T, Mitani K, Kurokawa M, Ogawa S, Tanaka K, Nishida J, Yazaki Y, Shibata Y, Hirai H: Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Mol Cell Biol 15:2383, 1995
48. Tanaka K, Tanaka T, Kurokawa M, Imai Y, Ogawa S, Mitani K, Yazaki Y, Hirai H: The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2β(CBFβ) in the nucleus more efficiently than wild-type AML1. Blood 91:1688, 1998
49. Takebe Y, Seiki M, Fujisawa J, Hoy P, Yokota K, Arai K, Yoshida M, Arai N: SRα promoter: An efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol 8:466, 1988
50. Brown AM, Scott MRD: Retroviral vectors. DNA cloning, vol. III. Oxford, UK, IRL, 1987
51. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989, p 16
52. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J: Mechanism of activation of the TGF-β receptor. Nature 370:341, 1994
53. Wieser R, Attisano L, Wrana JL, Massagué J: Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 13:7239, 1993
54. Bassing CH, Yingling JM, Howe DJ, Wang T, He WW, Gustafson ML, Shah P. Donahoe PK, Wang XF: A transforming growth factor β type I receptor that signals to activate gene expression. Science 263:87,1994
55. Carcamo J, Weis FM, Ventura F, Wieser R, Wrana JL, Attisano L, Massagué J: Type I receptors specify growth-inhibitory and transcrip- tional responses to transforming growth factor β and activin. Mol Cell Biol 14:3810, 1994
56. Carcamo J, Zentella A, Massagué J: Disruption of transforming growth factor β signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol 15:1573, 1995
57. Ohta M, Greenberger JS, Anklesaria P, Bassols A. Massagué J: Two forms of transforming growth factor-β distinguished by multipotential haematopoietic progenitor cells. Nature 329:539, 1987
58. Migliaccio G, Migliaccio AR, Kreide BL, Rovera G. Adamson JW: Selection of lineage-restricted cell lines immortalized at different stages of hematopietic differentiation from murine cell line 32D. J Cell Biol 109:833, 1989
59. Wagner RW. Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C, Froehler BC: Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260:1510, 1993
60. Bengal E, Ransone L, Scharfmann R, Dwarki VJ, Tapscott SJ, Weintraub H, Verma IM: Functional antagonism between c-Jun and MyoD proteins: A direct physical association. Cell 68:507, 1992
61. Levine M, Manley JL: Transcriptional repression of eukaryotic promoters. Cell 59:405, 1989
62. Yingling JM, Datto MB, Wong C, Frederick JP, Liberati NT, Wang X-F: Tumor suppressor Smad4 is a transforming growth factor β-inducible DNA binding protein. Mol Cell Biol 17:7019, 1997
63. Zawel L, Dai JL, Buckhaults P. Zhou S, Kinzler KW, Vogelstein B. Kern SE: Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1:611, 1998
64. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gaulthier J-M: Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type I gene. EMBO J 17:3091, 1998
65. Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK: The immunophilin FKBP12 functions as a common inhibitor of the TGF β family type I receptors. Cell 86:435, 1996
66. Chen Y-G, Fang L, Massagué J: Mechanism of TGFβ receptor inhibition by FKBP12. EMBO J 16:3866, 1997
67. Abraham SE, Carter MC, Moran E: Transforming growth factor β 1 (TGF β 1) reduces cellular levels of p34cdc2, and this effect is abrogated by adenovirus independently of the E1A-associated pRB binding activity. Mol Biol Cell 3:655, 1992
68. Imamura T, Takase A, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K: Smad6 inhibits signalling by the TGF-β superfamily. Nature 389:622, 1997
69. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu Y, Grinnell BW, Richardson MA, Topper JN, Gimbbrone MA, Wrana JL, Falb D: The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 89:1166, 1997
70. Nakao A, Afrakhte M, Morén A, Nakayama T, Christian JL, Heuchel R. Itoh S, Kawabata M, Heldin N-E, Heldin C-H, ten Dijke P: Identification of Srnad7. a TGFβ-inducible antagonist of TGF-β signalling. Nature 389:631, 1997
71. Bruno E, Miller ME, Huffman R: Interacting cytokines regulate in vitro human megakaryocytopoiesis. Blood 73:671, 1989
72. Kuter DJ, Gminski DM, Rosenberg RD: Transforming growth factor β inhibits megakaryocyte growth and endomitosis. Blood 79:619, 1992
73. Carapeti M, Goldman JM, Cross NC: Overexpression of EVI-1 in blast crisis of chronic myeloid leukemia. Leukemia 10:1561, 1996
74. Pintado T, Ferro MT, San RC, Mayayo M, Larana JG: Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 55:535, 1985
75. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E. Kinzler KW, Vogelstein B, Brattain M, Willson JKV: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268:1336, 1995
76. Riggins GL, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B: Mad-related genes in the human. Nat Genet 13:347, 1996
77. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JKV, Markowitz SD, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B: Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13:347, 1996
78. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da CL, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350, 1996
79. Kim SK, Fan Y, Papadimitrakopoulou V, dayman G. Hittelman WN, Hong WK, Lotan R, Mao L: DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 56:2519, 1996
80. Nagatake M, Takagi Y, Osada H, Uchida K. Mitsudomi T, Saji S, Shimokata K, Takahashi T, Takahashi T: Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 56:2718, 1996
81. Uchida K, Nagatake M. Osada H, Yatabe Y, Kondo M, Mitsudomi T, Masuda A, Takahashi T, Takahashi T: Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res 56:5583, 1996
82. Barrett MT, Schutte M, Kern SE, Reid BJ: Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res 56:4351, 1996
83. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RJ, Meltzer PS, Hahn SA, Kern SE: DPC4 gene in various tumor types. Cancer Res 56:2527, 1996
84. Frank CJ, McClatchey KD, Devaney KO, Carey TE: Evidence that loss of chromosome 18q is associated with tumor progression. Cancer Res 57:824, 1997
85. Hata A, Lo RS, Wotton D, Lagna G, Massagué J: Mutations increasing autoinhibition inactivate tumor suppressors Smad2 and Smad4. Nature 388:82, 1997
86. Wu R-Y, Zhang Y. Feng X-H, Derynck R: Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4. Mol Cell Biol 17:2521, 1997
87. Bruno E, Horrigan SK, Van Den Berg D, Rozler E, Fitting PR, Moss ST, Westbrook C, Hoffman R: The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-β on human hematopoiesis. Blood 91:1917, 1998